APA (7th ed.) Citation

C, A., O, A., LD, B., J, M., R, T., S, I., . . . B, M. (2026). The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation. Current obesity reports, 15(1), . https://doi.org/10.1007/s13679-026-00707-6

Chicago Style (17th ed.) Citation

C, Albor, et al. "The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation." Current Obesity Reports 15, no. 1 (2026). https://doi.org/10.1007/s13679-026-00707-6.

MLA (9th ed.) Citation

C, Albor, et al. "The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation." Current Obesity Reports, vol. 15, no. 1, 2026, https://doi.org/10.1007/s13679-026-00707-6.